GlassScriptPhysician profile
Luis A Polo
NPI 1831624899
$69,813.23
in general payments reported to CMS, 2019-2025
32 companies · $6,829 in 2025
The $6,829 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15K · 2022: $9,012 · 2023: $23K · 2024: $16K · 2025: $6,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Honoraria: $12K · Travel and Lodging: $7,285 · Food and Beverage: $6,956 · Consulting Fee: $2,300 · Education: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,400.00 |
| Honoraria | $11,500.00 |
| Travel and Lodging | $7,285.06 |
| Food and Beverage | $6,955.90 |
| Consulting Fee | $2,300.00 |
| Education | $358.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $31,879.10 | 2021-2025 | Lokelma, Farxiga |
| Horizon Therapeutics Plc | $16,692.42 | 2021-2023 | Krystexxa |
| Amgen INC. | $14,381.18 | 2022-2025 | Krystexxa, Tavneos |
| Vifor Pharma, INC. | $943.56 | 2021-2025 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $921.76 | 2021-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $920.48 | 2021-2025 | Acthar, Terlivaz |
| Otsuka America Pharmaceutical, INC. | $508.72 | 2021-2025 | Jynarque |
| Ardelyx, INC. | $500.38 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Travere Therapeutics, INC. | $466.47 | 2022-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $430.08 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $250.77 | 2024-2025 | |
| Averitas Pharma INC. | $231.29 | 2024-2025 | Qutenza |
| Opko Pharmaceuticals, LLC | $227.58 | 2021-2023 | Rayaldee |
| Calliditas Therapeutics US INC. | $176.57 | 2022-2025 | Tarpeyo |
| Novo Nordisk INC | $170.14 | 2022-2025 | Wegovy, Ozempic |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $145.51 | 2021-2023 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.40 | 2023-2025 | Jardiance |
| Baxter Healthcare | $128.15 | 2025 | Renal - Acute |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $108.91 | 2024 | |
| Pharmacosmos Therapeutics INC. | $95.52 | 2022-2023 | Monoferric |
| Fresenius USA Marketing, INC. | $86.22 | 2022-2024 | |
| Akebia Therapeutics INC | $62.17 | 2021-2024 | Auryxia, Vafseo |
| Lilly USA, LLC | $61.75 | 2023-2024 | Jardiance |
| Galderma Laboratories, L.P. | $55.69 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $40.57 | 2021-2023 | |
| Glaxosmithkline, LLC. | $38.84 | 2023-2025 | Shingrix, Arexvy, Benlysta |
| Cormedix INC. | $37.50 | 2025 | Defencath |
| Nevro Corp. | $29.44 | 2024 | Senza |
| Cvrx, INC. | $25.68 | 2025 | Barostim Neo System |
| Takeda Pharmaceuticals U.S.A., INC. | $24.22 | 2023 | Gattex |
| Leadiant Biosciences, INC. | $18.00 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.16 | 2023 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Polo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.